Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients

Data from LUMINA (LXXV), a multiethnic US cohort

R. Willis, A. M. Seif, G. McGwin, L. A. Martinez-Martinez, Emilio Gonzalez, N. Dang, E. Papalardo, J. Liu, L. M. Vilá, J. D. Reveille, G. S. Alarcón, S. S. Pierangeli

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: We sought to determine the effect of hydroxychloroquine therapy on the levels proinflammatory/prothrombotic markers and disease activity scores in patients with systemic lupus erythematosus (SLE) in a multiethnic, multi-center cohort (LUMINA). Methods: Plasma/serum samples from SLE patients (n=35) were evaluated at baseline and after hydroxychloroquine treatment. Disease activity was assessed using SLAM-R scores. Interferon (IFN)-α2, interleukin (IL)-1β, IL-6, IL-8, inducible protein (IP)-10, monocyte chemotactic protein-1, tumor necrosis factor (TNF)-α and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Anticardiolipin antibodies were evaluated using ELISA assays. Thirty-two frequency-matched plasma/serum samples from healthy donors were used as controls. Results: Levels of IL-6, IP-10, sCD40L, IFN-α and TNF-α were significantly elevated in SLE patients versus controls. There was a positive but moderate correlation between SLAM-R scores at baseline and levels of IFN-α (p=0.0546). Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p=0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-α (p=0.0087). Conclusions: Hydroxychloroquine therapy resulted in significant clinical improvement in SLE patients, which strongly correlated with reductions in IFN-α levels. This indicates an important role for the inhibition of endogenous TLR activation in the action of hydroxychloroquine in SLE and provides additional evidence for the importance of type I interferons in the pathogenesis of SLE. This study underscores the use of hydroxychloroquine in the treatment of SLE.

Original languageEnglish (US)
Pages (from-to)830-835
Number of pages6
JournalLupus
Volume21
Issue number8
DOIs
StatePublished - Jul 2012

Fingerprint

Hydroxychloroquine
Systemic Lupus Erythematosus
Cytokines
Interferons
CD40 Ligand
Therapeutics
Interleukin-6
Tumor Necrosis Factor-alpha
Anticardiolipin Antibodies
Interferon Type I
Chemokine CCL2
Serum
Interleukin-8
Interleukin-1
Immunoassay
Proteins
Enzyme-Linked Immunosorbent Assay
Tissue Donors

Keywords

  • biomarkers of inflammation
  • biomarkers of thrombosis
  • hydroxychloroquine
  • Lupus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients : Data from LUMINA (LXXV), a multiethnic US cohort. / Willis, R.; Seif, A. M.; McGwin, G.; Martinez-Martinez, L. A.; Gonzalez, Emilio; Dang, N.; Papalardo, E.; Liu, J.; Vilá, L. M.; Reveille, J. D.; Alarcón, G. S.; Pierangeli, S. S.

In: Lupus, Vol. 21, No. 8, 07.2012, p. 830-835.

Research output: Contribution to journalArticle

Willis, R, Seif, AM, McGwin, G, Martinez-Martinez, LA, Gonzalez, E, Dang, N, Papalardo, E, Liu, J, Vilá, LM, Reveille, JD, Alarcón, GS & Pierangeli, SS 2012, 'Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort', Lupus, vol. 21, no. 8, pp. 830-835. https://doi.org/10.1177/0961203312437270
Willis, R. ; Seif, A. M. ; McGwin, G. ; Martinez-Martinez, L. A. ; Gonzalez, Emilio ; Dang, N. ; Papalardo, E. ; Liu, J. ; Vilá, L. M. ; Reveille, J. D. ; Alarcón, G. S. ; Pierangeli, S. S. / Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients : Data from LUMINA (LXXV), a multiethnic US cohort. In: Lupus. 2012 ; Vol. 21, No. 8. pp. 830-835.
@article{e59aaa3c05604a2cbb6701da4d88f8a0,
title = "Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort",
abstract = "Objective: We sought to determine the effect of hydroxychloroquine therapy on the levels proinflammatory/prothrombotic markers and disease activity scores in patients with systemic lupus erythematosus (SLE) in a multiethnic, multi-center cohort (LUMINA). Methods: Plasma/serum samples from SLE patients (n=35) were evaluated at baseline and after hydroxychloroquine treatment. Disease activity was assessed using SLAM-R scores. Interferon (IFN)-α2, interleukin (IL)-1β, IL-6, IL-8, inducible protein (IP)-10, monocyte chemotactic protein-1, tumor necrosis factor (TNF)-α and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Anticardiolipin antibodies were evaluated using ELISA assays. Thirty-two frequency-matched plasma/serum samples from healthy donors were used as controls. Results: Levels of IL-6, IP-10, sCD40L, IFN-α and TNF-α were significantly elevated in SLE patients versus controls. There was a positive but moderate correlation between SLAM-R scores at baseline and levels of IFN-α (p=0.0546). Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p=0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-α (p=0.0087). Conclusions: Hydroxychloroquine therapy resulted in significant clinical improvement in SLE patients, which strongly correlated with reductions in IFN-α levels. This indicates an important role for the inhibition of endogenous TLR activation in the action of hydroxychloroquine in SLE and provides additional evidence for the importance of type I interferons in the pathogenesis of SLE. This study underscores the use of hydroxychloroquine in the treatment of SLE.",
keywords = "biomarkers of inflammation, biomarkers of thrombosis, hydroxychloroquine, Lupus",
author = "R. Willis and Seif, {A. M.} and G. McGwin and Martinez-Martinez, {L. A.} and Emilio Gonzalez and N. Dang and E. Papalardo and J. Liu and Vil{\'a}, {L. M.} and Reveille, {J. D.} and Alarc{\'o}n, {G. S.} and Pierangeli, {S. S.}",
year = "2012",
month = "7",
doi = "10.1177/0961203312437270",
language = "English (US)",
volume = "21",
pages = "830--835",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients

T2 - Data from LUMINA (LXXV), a multiethnic US cohort

AU - Willis, R.

AU - Seif, A. M.

AU - McGwin, G.

AU - Martinez-Martinez, L. A.

AU - Gonzalez, Emilio

AU - Dang, N.

AU - Papalardo, E.

AU - Liu, J.

AU - Vilá, L. M.

AU - Reveille, J. D.

AU - Alarcón, G. S.

AU - Pierangeli, S. S.

PY - 2012/7

Y1 - 2012/7

N2 - Objective: We sought to determine the effect of hydroxychloroquine therapy on the levels proinflammatory/prothrombotic markers and disease activity scores in patients with systemic lupus erythematosus (SLE) in a multiethnic, multi-center cohort (LUMINA). Methods: Plasma/serum samples from SLE patients (n=35) were evaluated at baseline and after hydroxychloroquine treatment. Disease activity was assessed using SLAM-R scores. Interferon (IFN)-α2, interleukin (IL)-1β, IL-6, IL-8, inducible protein (IP)-10, monocyte chemotactic protein-1, tumor necrosis factor (TNF)-α and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Anticardiolipin antibodies were evaluated using ELISA assays. Thirty-two frequency-matched plasma/serum samples from healthy donors were used as controls. Results: Levels of IL-6, IP-10, sCD40L, IFN-α and TNF-α were significantly elevated in SLE patients versus controls. There was a positive but moderate correlation between SLAM-R scores at baseline and levels of IFN-α (p=0.0546). Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p=0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-α (p=0.0087). Conclusions: Hydroxychloroquine therapy resulted in significant clinical improvement in SLE patients, which strongly correlated with reductions in IFN-α levels. This indicates an important role for the inhibition of endogenous TLR activation in the action of hydroxychloroquine in SLE and provides additional evidence for the importance of type I interferons in the pathogenesis of SLE. This study underscores the use of hydroxychloroquine in the treatment of SLE.

AB - Objective: We sought to determine the effect of hydroxychloroquine therapy on the levels proinflammatory/prothrombotic markers and disease activity scores in patients with systemic lupus erythematosus (SLE) in a multiethnic, multi-center cohort (LUMINA). Methods: Plasma/serum samples from SLE patients (n=35) were evaluated at baseline and after hydroxychloroquine treatment. Disease activity was assessed using SLAM-R scores. Interferon (IFN)-α2, interleukin (IL)-1β, IL-6, IL-8, inducible protein (IP)-10, monocyte chemotactic protein-1, tumor necrosis factor (TNF)-α and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Anticardiolipin antibodies were evaluated using ELISA assays. Thirty-two frequency-matched plasma/serum samples from healthy donors were used as controls. Results: Levels of IL-6, IP-10, sCD40L, IFN-α and TNF-α were significantly elevated in SLE patients versus controls. There was a positive but moderate correlation between SLAM-R scores at baseline and levels of IFN-α (p=0.0546). Hydroxychloroquine therapy resulted in a significant decrease in SLAM-R scores (p=0.0157), and the decrease in SLAM-R after hydroxychloroquine therapy strongly correlated with decreases in IFN-α (p=0.0087). Conclusions: Hydroxychloroquine therapy resulted in significant clinical improvement in SLE patients, which strongly correlated with reductions in IFN-α levels. This indicates an important role for the inhibition of endogenous TLR activation in the action of hydroxychloroquine in SLE and provides additional evidence for the importance of type I interferons in the pathogenesis of SLE. This study underscores the use of hydroxychloroquine in the treatment of SLE.

KW - biomarkers of inflammation

KW - biomarkers of thrombosis

KW - hydroxychloroquine

KW - Lupus

UR - http://www.scopus.com/inward/record.url?scp=84861835445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861835445&partnerID=8YFLogxK

U2 - 10.1177/0961203312437270

DO - 10.1177/0961203312437270

M3 - Article

VL - 21

SP - 830

EP - 835

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 8

ER -